<DOC>
	<DOCNO>NCT00065182</DOCNO>
	<brief_summary>The purpose study compare efficacy safety weekly regimen two FDA approve drug combination versus one FDA approve drug subject advance non-small cell lung cancer receive one previous chemotherapy exclude TAXOTERE HYCAMTIN .</brief_summary>
	<brief_title>Comparison IV Topotecan/Docetaxel Docetaxel Alone Second-Line Stage IIIB/IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Inclusion criterion : Written inform consent At least 18 year old Confirmed advance nonsmall cell lung carcinoma ( NSCLC ) Received one prior chemotherapy metastatic NSCLC exclude TAXOTERE HYCAMTIN . In addition , subject allow previously receive noncytotoxic therapy , endothelial growth factor receptor ( EGFR ) angiogenesis inhibitor . Presence either measurable nonmeasurable disease radiologic study physical examination . Full recovery least 21 day prior treatment NSCLC ; 42 day treatment mitomycin nitrosureas 30 day prior noncytotoxic therapy . At least 3 week since last major surgery ( less period acceptable deem best interest patient ) . At least 7 day since prior radiotherapy . A probable life expectance least 3 month . Adequate bone marrow reserve , CBC/Platelet , kidney liver function . Exclusion criterion : Concomitant malignancy malignancy within last five year . Symptoms brain metastasis require treatment steroid . Active infection . Severe medical problem diagnosis NSCLC would limit ability subject follow study guideline expose subject extreme risk . Ongoing plan chemotherapy ( treatment study ) , immunotherapy , radiotherapy , investigational therapy treatment NSCLC . Use investigational drug within 30 day 5 halflives prior first dose study medication . Women pregnant lactating . Subjects childbearing potential refusing practice adequate contraception . Prior treatment history allergic reaction either HYCAMTIN TAXOTERE . Subjects receive steroid premedication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Stage IIIB/IV</keyword>
	<keyword>topotecan</keyword>
	<keyword>docetaxel</keyword>
	<keyword>TAXOTERE</keyword>
	<keyword>HYCAMTIN</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>Advanced</keyword>
	<keyword>NSCLC</keyword>
</DOC>